Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multi-center, Open-label Study of Epitinib Succinate (HMPL-813) in Treating Patients With Glioblastoma

NCT03231501 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.

NCT NCT03231501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03231501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multi-center, Open-label Study of Epitinib Succinate (HMPL-813) in Treating Patients With Glioblastoma
Lead sponsor
Hutchison Medipharma Limited
Phase
Phase 1
Overall status
Unknown status
Start date
January 26, 2018
Completion date
August 31, 2020
Enrollment
29 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma